Drugs / TRV120027
TRV120027
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04419610 | Oct 2020 → May 2021 | COVID-19 | Imperial College London | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01444872 | Aug 2011 → May 2012 | heart failure, kidney disorder | Trevena Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01187836 | Dec 2010 → Mar 2012 | heart failure | Trevena Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01966601 | Dec 2013 → Mar 2016 | heart failure | Trevena Inc. | Completed | Missed primary |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT04924660 | Jul 2021 → Oct 2023 | COVID-19 | Sean Collins | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2021-09-30 | Trevena Inc. | Results Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients trevena.com ↗
The results showed that TRV027 was well-tolerated and provided initial evidence of its potential to improve biomarker and clinical endpoints associated with COVID-19 disease severity and progression. |
| 2016-05-16 | Trevena Inc. | Results Trevena Reports TRV027 Did Not Achieve Primary or Secondary Endpoints in BLAST-AHF Phase 2b Trial in Acute Heart Failure trevena.com ↗
Trevena, Inc. (NASDAQ:TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the company’s TRV027 failed to meet either the primary or secondary endpoints in the Phase 2b BLAST-AHF study in acute heart failure (AHF). |
| 2015-03-09 | Trevena Inc. | Results Trevena completes interim analysis and announces plans for ongoing Phase 2b BLAST-AHF trial of TRV027 in acute heart failure trevena.com ↗
Upon reviewing the data, the data safety monitoring board (DSMB) and the BLAST-AHF Steering Committee recommended that future enrollment be weighted to the most promising dose of 5 mg/hr. |
| 2013-07-08 | Trevena Inc. | Results Journal of Clinical Pharmacology Publishes First Clinical Experience with Trevena's Heart Failure Biased Ligand TRV027 trevena.com ↗
TRV027 was safe and well-tolerated, with a usefully short half-life and dose-proportional increases in systemic exposure. |
| 2013-03-08 | Trevena Inc. | Results Trevena to present results of TRV027 Phase 2a Study in Patients with Advanced Heart Failure trevena.com ↗
Trevena successfully completed the Phase 2a study in October 2012, in which TRV027 was generally well-tolerated and produced a beneficial set of hemodynamic effects. |
| 2012-09-07 | Trevena Inc. | Results Trevena Presents Phase 1 Clinical Data for TRV027, a β-arrestin Biased AT1R Ligand, at the 2012 Heart Failure Society of America Meeting trevena.com ↗ |
| 2012-09-04 | Trevena Inc. | Results Trevena Acute Heart Failure Drug TRV027 Unloads the Heart and Maintains Renal Function When Co-administered with Furosemide in Dog Heart Failure Model trevena.com ↗
These findings indicate that TRV027 may work additively or synergistically with loop diuretics like furosemide, which are current standard of care for treating acute heart failure. |
| 2011-09-12 | Trevena Inc. | Results Cardiorenal Actions of Trevena Biased Ligand Heart Failure Drug Explained in Mayo Clinic Publication and Presentations trevena.com ↗
The data published this month in Circulation:Heart Failure shows that TRV027 rapidly and reversibly corrects hemodynamic parameters altered in paced heart failure canines, including both vascular and cardiac measures, while preserving renal function. |
| 2010-09-13 | Trevena Inc. | Results Trevena Presents Preclinical Data for TRV120027, a Biased AT1R Ligand, at the 14th Annual Heart Failure Society of America Meeting trevena.com ↗
In a canine preclinical model of paced heart failure, TRV120027 showed a beneficial profile, causing cardiac unloading actions while preserving renal function. |
| 2010-06-11 | Trevena Inc. | Results Trevena Data Showcasing GPCR Biased Ligands Featured at Scientific Conferences trevena.com ↗
These oral presentations highlight Trevena's research demonstrating that ligand bias at the angiotensin II type I receptor (AT1R) translates into differentiable and beneficial cardiovascular pharmacology in vivo. |
All press releases naming this drug 25 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRV120027 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01187836 ↗ |
| Known as | Formerly known as TRV120027 | “Formerly known as TRV120027” NCT01966601 ↗ |
| Known as | Sar-val-tyr-ile-his-pro-d-ala-oh | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297447 ↗ |
| Known as | TRV-027 | “2 investigational RAS agents, TXA-127 (synthetic angiotensin [1-7]) and TRV-027 (an angiotensin II type 1 receptor-biased ligand)” PMID 37039791 ↗ Apr 2023 |
| Action | Activate | “TRV027 is a similar peptide to Ang(1-7) but is a much more potent biased agonist at AT1R than Ang(1-7)” NCT04419610 ↗ |
| Action | Inhibit | “Type-1 angiotensin II receptor antagonist” CHEMBL4297447 ↗ |
| Modality | Peptide | “An investigational peptide biased agonist of the AT1 receptor.” NCT04924660 ↗ |
| Route | Intravenous | “TRV120027 (or a placebo) intravenous infusion will be given to people with heart failure.” NCT01187836 ↗ |
| Target | AGTR1 | “Type-1 angiotensin II receptor antagonist” CHEMBL4297447 ↗ |